Member Info for nursesteve

Early signs of a further shift up ?

I think it was about 5m traded on Friday and so far today 4m against an average daily of 2.7: GLA

The volumes and price rising suggest that someone is building a stake here. Prior to showing their hand with an offer? Partnership Deal? 🤔

Very happy with my top up this morning - should see the back of 65p soon GLA

I’d be very surprised if the news rich period we are entering isn’t full of positives.

The news we’ve had recently indicates AVACTA is a very different company to when ‘big Al’ was in charge. GLA

I’d say looking at the price paid it is much more likely to have been a buy.

‘Money goes to money’ there’s serious money to be made here and this shows someone with serious money knows that

Thanks T0n1c 👍🏻😀 GL

Anyone got a link to the presentation yesterday?

Thoroughly derisked now. Much more news to come very soon.

Then wait for a bid from big Pharma to really accelerate the value!

GLALTH’s & just any who hold here! 😁

Nice - from X - Hemogenyx could reach the clinic in Estonia in as little as 3–6 months, enabling treatments sooner than broader commercialization routes. This represents a strategic "bridge" for early access in a high-need indication.

So many de-rampers 🩳 🔥 😂

Could this be a route to revenue and validation for Avacta?

From this mornings RNS on Hemo

"permits the use of certain advanced therapy medicinal products ("ATMPs") that have not yet been authorized for commercial marketing to treat an unlimited number of patients, subject to sufficient preclinical or Phase I clinical trials data. The scheme also allows innovators to apply for reimbursement of treatment costs through the Estonian National Health Fund."

Where one leads others follow …

This collaboration represents the first potential near-term revenue opportunity for HG-CT- 💰

Many More to follow! GLA! 😁

Is he getting the band back together? 😂

I’d say a retrace I’d much more likely - anyone buying first thing this morning will have been able to bank a decent return for their mornings work. With a possibility to buy more after today’s ride up is over.

Just reading N4P’s RNS this morning

“Targeting RNA therapies to specific cells and tissues to maximise efficacy and reduce systemic toxicity is a holy grail for nucleic acid therapeutics developers and is challenging to achieve with established RNA delivery methods.”

They seem to be the nearest competitor to Avacta but several steps behind IMHO

Added a few GLA

So on the 4th when the company announced they were planning on applying for inclusion in US National Comprehensive Cancer Network guidelines later this year following a study that confirmed utilisation of the EpiSwitch CiRT test. One of their II chose to reduce their holding. Selling the news? Not showing a lot of faith that it would get approval?

Those holding here need Iain Ross to sign a deal or deals that bring revenue in or there will be others looking to exit rather than hold. GLA

I’m looking forward to the update in Oct on SGC which has no standard therapy.

When they presented at AACR in April there was a disease control rate of 91% and the median progress free survival hadn’t been reached (but had more than doubled). Subsequently in June a new partial response was announced.

Might this be the indication that sees AVA6000 getting approval from the FDA & being licensed? GLA